Neumora Therapeutics (NMRA) Cash & Equivalents (2022 - 2026)

Neumora Therapeutics' Cash & Equivalents history runs 5 years deep, the most recent figure standing at $147.1 million for Q1 2026.

• In Q1 2026, Cash & Equivalents rose 15.93% year-over-year to $147.1 million; the TTM figure through Mar 2026 stood at $147.1 million (up 15.93% YoY), while the FY2025 annual figure was $182.5 million, up 28.41% from the prior year.
• Cash & Equivalents for Q1 2026 stood at $147.1 million, down from $182.5 million in the prior quarter.
• The five-year high for Cash & Equivalents was $412.3 million in Q3 2023, with the low at $124.5 million in Q2 2025.
• The 5-year median for Cash & Equivalents is $182.9 million (2024), against an average of $210.4 million.
• The sharpest annual moves came in 2023 and 2024: Cash & Equivalents jumped 63.27% in 2023, then slumped 62.0% in 2024.
• Neumora Therapeutics' Cash & Equivalents stood at $240.9 million in 2022, then jumped by 55.24% to $374.0 million in 2023, then plunged by 62.0% to $142.1 million in 2024, then advanced by 28.41% to $182.5 million in 2025, then retreated by 19.43% to $147.1 million in 2026.
• Business Quant data shows NMRA's Cash & Equivalents at $147.1 million in Q1 2026, $182.5 million in Q4 2025, and $129.1 million in Q3 2025.